NYS AG Expands Pharmaceutical probe – Forest Labs Wed, 30 Jun 2004 The New York Times reports (below) that New York State Attorney General, Eliot Spitzer, is broadening his legal investigation. “Mr. Spitzer said in a speech on Monday to health care . . . Continue reading →
Today’s (6/30/04) editorial, “Missing Drug Data,” misses the point and argues with the pharmaceutical industry and its allies in the Congress, the NIH and the FDA that data can be selectively reported to satisfy commercial interests. This is a blatant attack on Karl Popper’s falsifiability principle on which empirical science depends to make progress. One needs all the data in order to verify the results of clinical or any other kind of research. Most academics and pundits know that any case can be made if allowed to manipulate the data and assumptions. The AMA, the medical journal editors, and Eliot Spitzer, all deserve applause from the Washington Post editor-not quibbling about the possible damage that somehow, somewhere might result from strict embrace of the principles and practice of scientific inquiry. It’s all about transparency.
John H. Noble, Jr. Continue reading →
Scientists Decode Secret of Getting NIH Grants – WSJ Mon, 28 Jun 2004 The Secret of Getting Grants: Marketing Helps University Win $350 Million a Year, by Bernard Wysocki, a front page article in The Wall Street Journal, provides insight into an . . . Continue reading →
Forest Labs Admits Concealment of data – Congressional Probe Expands Sat, 26 Jun 2004 New York Times business reporter, Barry Meier, reports, “Forest officials had not told a medical journal about a failed unpublished study in 2002 of Celexa use in children . . . Continue reading →
To: Thomas Insel MD; Tommy Thompson Re: Published NIMH Prozac Trial Report Concealed Suicide Attempts by Teens ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) Tel. 212-595-8974 Fax: 212-595-9086 142 West End Ave. Suite 28P New York, NY 10023 Related Link: NIMH Response to . . . Continue reading →
To: Thomas Insel MD; Tommy Thompson Re: Published NIMH Prozac Trial Report Concealed Suicide Attempts by Teens ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) Tel. 212-595-8974 Fax: 212-595-9086 142 West End Ave. Suite 28P New York, NY 10023 Board of Directors: Vera Hassner . . . Continue reading →
Recent revelations indicate that pharmaceutical companies have selectively reported partial (favorable) clinical trial results from pediatric antidepressant trials and concealed evidence of harm from physicians, other health care professionals, and the public. It is universally agreed in the literature that failure to disclose all trial results compromises physicians’ ability to provide professional care – thereby increasing the likelihood of causing preventable harm. More generally, failure to disclose trial results in scientific publications taints the scientific literature (by rendering it not credible) and, as New York State Attorney General Elliot Spitzer charged recently, constitutes plain and simple fraud.
Antidepressants – USA Today Editorial / AHRP OpEd/ WSJ Editorial Bashes Spitzer Mon, 21 Jun 2004 The debate about antidepressants, concealment of clinical trial data, and failure to warn about a suicide risk, is reaching an ever broader public. An editorial in . . . Continue reading →
Ethics of Non-Consensual Human Experimentation – NPR Sat, 20 Mar 2004 Below is a transcript of an NPR discussion about the ethics of a non-consensual artificial blood experiment. The discussion was slanted toward proceeding with highest risk non-consensual experimentation on the basis . . . Continue reading →
NYS Attorney General files suit against GlaxoSmithKline for Concealing Drug Information Wed, 2 Jun 2004 The most positive development in the antidepressant drug saga is the filing of a much needed lawsuit by Eliot Spitzer, New York State Attorney General. The suit . . . Continue reading →